tirzepatide and svt (ZEPBOUND) Approved for Chronic Weight Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Semaglutide vs. Tirzepatide for Weight

Weight loss injections like semaglutide, tirzepatide, and liraglutide do not fall into these high-risk categories

If headaches persist beyond this window, a provider review of dose, hydration protocol, and potential contributors is warranted

Semaglutide and Cardiovascular Outcomes [PMID: 38381682] Laboratory literature summary: Semaglutide and Cardiovascular Outcomes

Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm (upper arm injections should be administered by a caregiver, not self-administered)

Semaglutide offers a personalized approach to weight management, helping reduce cravings and support long-term lifestyle changes